Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05425771
Other study ID # ARMA01
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date July 14, 2022
Est. completion date May 31, 2023

Study information

Verified date July 2022
Source Klinikum Garmisch-Patenkirchen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pilot study of the possible clinical response to anti reflux mucosal ablation in patients with chronic refractory reflux disease


Description:

Prospective, non-controlled, monocentric pilot study in patients with therapy-refractory reflux symptoms under proton pump inhibitor (PPI) therapy or intolerance of the necessary therapy or rapid recurrence of the symptoms with tapering therapy. The symptoms must have existed for >6 months. Gastroesophageal reflux disease (GERD) must be diagnosed before inclusion in the study. This is the case if either erosive reflux esophagitis according to Los Angeles classification grades A-D is present or non-erosive reflux disease (NERD) has been confirmed by a 24-hour pH measurement/impedance measurement. The measurement must show either an increased number of reflux events or a prolonged time under reflux. In addition, there must be a high correlation between symptoms and reflux events when reporting symptom events. The GERD-HRQL score is queried for the clinical quantification of symptoms. An esophageal motility disorder, especially achalasia or relevant hypomotility must be ruled out in an high resolution esophageal manometry. A relevant gastric emptying disorder is ruled out using a C13 octanoate breath test. Patients with a Hill IV axial hernia, a paraesophageal hernia, or Barrett's esophagus are not included. Pregnancy must be ruled out in women of childbearing age. The ARMA procedure is explained to the patient in detail with the expected benefits and risks in oral and written form. In addition, alternative treatments such as surgical fundoplication are discussed. In the ARMA procedure, a gastroscopy is performed under sedation with propofol. Argon plasma coagulation (APC) is performed in inversion at the gastroesophageal junction in a crescent or horseshoe shape over a width of 1.5 - 2 cm, as described in the original publication. The intended destruction of the uppermost layer of the gastroesophageal junction is intended to induce an inflammatory reaction with subsequent shrinkage of the corresponding tissue section. This leads to a tightening of the gastroesophageal junction with subsequent improved tightness, so that reflux events occur less frequently. Patients will be monitored in hospital for 48 hours. The existing drug therapy is continued for 4 weeks and then tapered off. Endoscopic and clinical follow-up checks take place after 2 and 6 months using gastroscopy and GERD-HRQL score.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 15
Est. completion date May 31, 2023
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - typical reflux symptoms more than 2x per week during PPI therapy more than 6 month - proof of gastro-esophageal reflux in pH metry oder pH/Impedance measurement Exclusion Criteria: - age < 18 y - primary motility disorder of the esophagus - hiatal hernia > 3 cm - Hill classification > III - pregnancy - coagulation disorder - mandatory intake of oral anticoagulation drugs

Study Design


Intervention

Procedure:
Anti Reflux Mucosa Ablation
Mucosa ablation with Argon plasma coagulation performed in inversion at the gastroesophageal junction in a crescent or horseshoe shape over a width of 1.5 - 2 cm in patients with refractory reflux symptoms

Locations

Country Name City State
Germany Klinikum Garmisch-Partenkirchen Garmisch-Partenkirchen Bayern

Sponsors (1)

Lead Sponsor Collaborator
Klinikum Garmisch-Patenkirchen

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary change of GERD-HRQL The Gastroesophageal Reflux Disease-Health Related Quality of Life (GERD-HRQL) is a standardized questionaire and a quantitative method of measuring symptom severity in gastroesophageal reflux disease (GERD). The results are from minimal 0 points up to 50 points. The higher the points, the greater the complaints. Before and after 2 and 6 Month
Primary Rate of major complications Recording of all major complication which require hospitalization day 1
Secondary Technical success nominal scale In this case, the abortion of the procedure or the subjective assessment of the examiner apply immediately after the end of the procedure.
The examiner evaluates the complete technical success as successful or unsuccessful
Day 1
Secondary change of DeMeester Score The DeMeester score is a scoring system at pH/Impendence measurement that quantifies esophageal acid exposure time in long-term pH monitoring. A DeMeester score of = 14.72 is considered physiological.
The score includes the following values:
Percentage of time with esophageal pH < 4 of total measurement time Percentage of time with pH < 4 during the waking phase (upright position) Percentage of time with pH < 4 during the sleep phase (lying position) Total number of reflux episodes during the measurement time Number of reflux episodes lasting > 5 min Duration of the longest reflux episode
Before and after 2 and 6 Month
Secondary change of reflux events Measurement of the number of events in the pH/Impendence measurement. A count <74 in 24 hours is considered normal. Before and after 2 and 6 Month
See also
  Status Clinical Trial Phase
Recruiting NCT05326113 - The Effect of Physiotherapy on Post POEM Reflux N/A
Enrolling by invitation NCT05023174 - Platelet Rich Plasma in Hiatal Hernia Repair N/A
Recruiting NCT05303298 - Evaluating Acid Reflux After Oesophageal Stenting Using Anti-reflux Stents N/A
Recruiting NCT05750186 - The Effect of Abdominal Massage Applied After Surgery N/A
Completed NCT03659487 - Comparison of Total and Partial Fundoplication During Surgery of Patients With Gastroesophageal Reflux Disease N/A
Completed NCT05634187 - One-stop-shop Endoscopy in Reflux-patients: Evaluation of ENT and GI Features
Terminated NCT02749071 - An Investigation of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System for the Treatment of Reflux N/A
Completed NCT04651829 - Suspicion of Non IgE-mediated Cow's Milk Protein Allergy: Prevalence and Evolution
Completed NCT00551473 - Open-label Comparison of 24hr Gastric pH on Days 1, 2, 7 With Once-daily Administration of Lavoltidine 40 mg. Phase 1
Completed NCT00405119 - A Study To Investigate The Effectiveness Of AH234844 (Lavoltidine) Compared With NEXIUM And Ranitidine. Phase 2
Completed NCT03959020 - Applying Long-term Follow-up to Improve Patient Selection in Laparoscopic Anti-reflux Surgery
Recruiting NCT04695171 - LINX Reflux Management System or Fundoplication Clinical Study in Patients With Hiatal Hernia >3 cm
Completed NCT04344964 - Endoscopy-related Phone Consultation During the COVID-19 Outbreak